Литература

1.             Коморбидная патология в клинической практике. Алгоритмы диагностики и лечения 2019г.  Кардиоваскулярная терапия и профилактика.

2019;18(1):5-66.

2.             Arnett D, Goodman R, Halperin J, at al. AHA/ACC/HHS strategies to enhance application of clinical practice guidelines in patients with cardiovascular disease and comorbid conditions. J Am Coll Cardiol. 2014;64:1851–1856.

3.             Kraemer H.C. Statistical issues in assessing comorbidity. Stat Med.1995; 14:721-723.

4.              van den Akker M., Buntinx F., Roos S., Knottnerus J.A.. Comorbidity or multimorbidity: what’s in a name? A review of the literature. Eur J Gen Pract. 1996; 2(2):65-70.

5.             van den Akker M., Buntinx F., Metsemakers J.F., Roos S., Knottnerus J.A. Multimorbidity in general practice: prevalence, incidence, and determinants of co-occurring chronic and recurrent diseases. J Clin Epidemiol, 1998; 51:367-375

6.             Fortin M., Bravo G., Hudon C., Vanasse A., Lapointe L. Prevalence of multimorbidity among adults seen in family practice. Ann Fam Med.2005; 3:223-228.

7.             Caughey G.E., Ramsay E.N., Vitry A.I., at al. Comorbid chronic diseases, discordant impact on mortality in older people: a 14-year longitudinal population study.J Epidemiol Community Health. 2010;64(12):1036-1042.

8.             Wang P.S., Avorn J., Brookhart M.A. Effects of noncardiovascular comorbidities on antihypertensive use in elderly hypertensives. Hypertension, 2005; 46(2):273-279

9.             Gijsen R., Hoeymans N., Schellevis F.G., Ruwaard D., Satariano W.A. Causes and consequences of comorbidity: a review. J Clin Epidemiol. 2001;54(7): 661—674.

10.         Grolla D.L., Tob T., Bombardierc C., Wright J.G. The development of a comorbidity index with physical function as the outcome. J Clin Epidemiol;2005; 58(6):595—602.

11.         Zinman B, Wanner C, Lachin J, at al. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. N Engl J Med. 2015;373(22):2117-2128

12.         Fitchett D, Zinman B, Wanner C,at al. Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOME trial. Eur Heart J.2016;37(19):1526-1534.

13.         Wiviott S, Raz I, Bonaca V, et al. Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med 2019; 380:347-357.

14.         Marso S, Daniels G, Brown-Frandsen K, at al. Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med.2016; 375:311-322.